Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012042391 - METHODS FOR THE DEVELOPMENT OF METZINCIN-SELECTIVE CATALYTIC CLEFT DIRECTED ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS

Publication Number WO/2012/042391
Publication Date 05.04.2012
International Application No. PCT/IB2011/002860
International Filing Date 01.10.2011
IPC
C07K 16/40 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
40against enzymes
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
A61P 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
Applicants
  • RAHMAN, Salman [GB]/[GB]
  • PATEL, Yatin [GB]/[GB]
Inventors
  • RAHMAN, Salman
  • PATEL, Yatin
Priority Data
61/389,17601.10.2010US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR THE DEVELOPMENT OF METZINCIN-SELECTIVE CATALYTIC CLEFT DIRECTED ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
(FR) PROCÉDÉ DE MISE AU POINT D'ANTICORPS DIRIGÉS CONTRE LA CREVASSE CATALYTIQUE ET SÉLECTIFS DES METZINCINES POUR DES APPLICATIONS THÉRAPEUTIQUES ET DIAGNOSTIQUES
Abstract
(EN)
In some aspects, general methods to develop highly selective inhibitory antibodies towards members of the metzincin superfamily of metalloproteases and their application for therapeutic and diagnostic uses are provided. The methods employ the generation of novel catalytic cleft-directed antibodies with neutralising selectivity for the targeted metzincin metalloendoproteinase employing immunogenic peptides encompassing the consensus metzincin catalytic motif. In some aspects, methods include the employment of such antibodies for therapeutic purposes and/or as an inhibitory component of an assay system allowing discrimination between the activity of the targeted metzincin and other endogenous metzincins within a biological sample. Such assays may be employed for diagnostic or prognostic purposes.
(FR)
Dans certains aspects, la présente invention concerne des procédés généraux de mise au point d'anticorps inhibiteurs hautement sélectifs dirigés contre la superfamille de métalloprotéases metzincines et leur application pour des utilisations thérapeutiques et diagnostiques. Les procédés utilisent la génération de nouveaux anticorps dirigés contre la crevasse catalytique avec une sélectivité de neutralisation pour la métalloendoprotéinase metzincine ciblée en utilisant des peptides immunogènes comprenant le motif catalytique consensus des metzincines. Dans certains aspects, les procédés comprennent l'utilisation de ces anticorps pour des fins thérapeutiques et/ou en tant que composant inhibiteur d'un système de test permettant la discrimination entre l'activité de la metzincine ciblée et d'autres metzincines endogènes dans un échantillon biologique. Ces tests peuvent être utilisés pour des fins diagnostiques et pronostiques.
Latest bibliographic data on file with the International Bureau